Gateway Biotechnology, Inc.

KENT, OH 44240

SBIR Award Summary

Total Number of Awards 4
Total Value of Awards $899K
First Award Date 05/01/14
Most Recent Award Date 09/21/17

Key Personnel

Last Name Name Awards Contact
KOPECKY BENJAMIN J KOPECKY 1
CHEN XIAOJIE CHEN 1
BAO JIANXIN BAO 2

4 Awards Won

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-16-303
Budget: 09/21/17 - 03/20/18

PROJECT SUMMARY The most common occupational and environmental hazard in this country is noise. It's not surprising, then, that noise-induced hearing loss (NIHL) is the second most common form of sensorineural hearing deficit, behind only age-related hearing loss (presbycusis). Although therapeutics that target the free radical pathway have show...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-16-303
Budget: 07/05/17 - 01/31/18

PROJECT SUMMARY In spite of recent new drug developments, platinum-based drugs such as cisplatin are still widely used to treat solid organ malignancies. Besides its limited efficacy, serious side effects have been associated with the use of cisplatin, such as bilateral and irreversible hearing loss. In the cochlea, cisplatin can trigger the pr...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-15-270
Budget: 05/01/16 - 10/31/16

? DESCRIPTION (provided by applicant): Noise is the most common occupational and environmental hazard, thus it is not surprising that noise-induced hearing loss (NIHL) is the second most common form of sensorineural hearing deficit, second only to age-related hearing loss. Although therapeutics that target the free radical pathway have shown p...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-13-234
Budget: 05/01/14 - 11/30/14

DESCRIPTION (provided by applicant): Noise is the most common occupational and environmental hazard, thus it is not surprising that noise-induced hearing loss (NIHL) is the second most common form of sensorineural hearing deficit, second only to age-related hearing loss (presbycusis). Although therapeutics that target the free radical pathway ha...